

PROJECT FINAL REPORT

Grant Agreement number: 295010

Project acronym: KHCCBIO

Project title: Supporting the Establishment of a Cancer Biobank for Jordan and its Neighbouring Countries Through Knowledge Transfer & Training

Funding Scheme: Supporting action

Period covered: from 15 November 2011 to 14 May 2014

Name of the scientific representative of the project's co-ordinator¹, Title and Organisation:

Dr. Maher A. Sughayer, King Hussein Cancer Center

Tel: +962-6-5300460 ext1551

Fax: +962-6-5300460 ext1552

E-mail: msughayer@khcc.jo

Project website address: <http://KHCCBIO.KHCC.JO>

¹ Usually the contact person of the coordinator as specified in Art. 8.1. of the Grant Agreement.

Furthermore, project logo, diagrams or photographs illustrating and promoting the work of the project (including videos, etc...), as well as the list of all beneficiaries with the corresponding contact names can be submitted without any restriction.

K H C C B I O



Consortium for Bio-Banking Jordan-Ireland

Pictures of the new KHCCBIO Cancer Biobank









KHCCBIO Kick-off meeting press conference





Training conducted at TCD and Biostór , Ireland for KHCCBIO technicians and pathologist







Training conducted for the document controller at Biostór, Ireland

Validation of the equipment during the annual consortium meeting held in Amman Jordan





Second Consortium meeting held in Amman Jordan





The Final International Conference Part of the Project Deliverables. Conference on Biobanking: Establishing the first Cancer Biobank in Jordan (10-11 APRIL, 2014), Le Meridian, Amman, Jordan.

King Hussein Cancer Center organized a conference titled “Conference on Cancer Biobanking: Establishing the First Cancer Biobank in Jordan,” which was sponsored by the FP7-EU program and considered as an initiative of KHCC with ESBB and WHO support. The conference was held under the patronage of HRH Princess Ghida Talal at the Le Meridian Hotel, Amman, Jordan on the 10th and 11th of April, 2014.

The conference featured plenary lectures delivered by renowned local, regional and international clinicians, researchers and biobankers. Invaluable knowledge was delivered, and new partnerships were established between biobanks all over the world. A scientific exhibition of pharmaceuticals, medical and clinical equipment/ items related to biobanking and other related products also took place to allow for discussion and exchange of information between relevant delegates and leading industrial companies.

International Speakers:

Prof. Jan-Eric Litton - Karolinska Institute, Sweden

Prof. Kurt Zatloukal - Institute of Pathology, Medical University of Graz, Graz

Prof. Pasquale De Blasio - Founding President of ESBB. Milan, Italy

Dr. Rita Lawlor - University of Verona, Verona, Italy

Dr. Marianne Henderson - National Cancer Institute, National Institutes of Health, USA

Dr. Maimuna Mendy - International Agency for Research on Cancer, Lyon, France

Dr. Manuel M. Morente - Spanish National Cancer Center, Madrid, Spain

Ms. Tanya Dimitrova - Policy Officer - EU; Brussels, Belgium

Mr. Ma'n H. Zawati - Centre of Genomics and Policy – McGill University, Canada

Regional and Local Speakers:

Prof. Mostafa Abolfotouh - King Saud Bin-Abdulaziz University for Health Sciences, Saudi Arabia

Dr. Rania M. Labib - Children's Cancer Hospital-Egypt

Dr. Sonia Abdelhak - Institute Pasteur de Tunis, Tunisia

Dr. Hadi Abderrahim - Qatar Biobank, Qatar

Dr. Ahmad Samir - Children's Cancer Hospital ,Egypt

Dr. Maher Sughayer – King Hussein Cancer Center

Dr. Lina Souan – King Hussein Cancer Center

Dr. Mamoun Ahram – Jordan University, Amman, Jordan

Topics

- Session 1: *History and Current Status of Biobanking*
- Session 2: *Biobanking in the Middle East & Low-Income Countries*
- Session 3: *Role of Biobanking in Public Health & Personalized Medicine*
- Session 4: *Ethics in Biobanking*
- Session 5: *Sustainability of Biobanks*
- Session 6: *Networking and Globalization of Biobanks*

Some of the conference's lectures and Interviews:

<http://www.youtube.com/watch?v=lpIX-FZOSo>

<http://www.youtube.com/watch?v=fT08xP7qJBc>

<http://www.youtube.com/watch?v=7nlmsnxD90>

<http://www.youtube.com/watch?v=pPkKWaVojac>

<http://www.youtube.com/watch?v=oa75R2RObNQ>

http://www.youtube.com/watch?v=z03CGt_HyzE

http://www.youtube.com/watch?v=Zf3B4gF_cBA

<http://www.youtube.com/watch?v=89nicZGOgb4>



KHCCBIO flyers

First Flyer

<p>KHCCBIO - Supporting the Establishment of a Cancer Biobank for Jordan and its Neighboring Countries Through Knowledge Transfer & Training</p> <p>In the post-genomics era of biomedical science, biospecimens are assuming an even more prominent role in efforts to identify the key genes, RNAs, proteins, and signaling networks involved in cancer and then use this information to detect cancer at its earliest stages and develop a personalized therapeutic regimen to treat cancer.</p> <p>Indeed, the very future of personalized medicine depends on the ability of researchers to compare the molecular workings from hundreds of biospecimens and tease out the differences that have diagnostic and therapeutic value. Unfortunately, the vast majority of the millions of biospecimens currently in collections around the world are not suitable for making the type of direct comparisons that modern cancer biology research demands.</p> <p>The reason is simple: no standard protocol has governed how surgeons collect tissue samples, how pathologists prepare those biospecimens, and how tissue banks store their collected biospecimens. And, given the exquisite sensitivity of today's analytical techniques, it is nearly impossible to distinguish between molecular fingerprints related to cancer and that arising from the way a given biospecimen was handled.</p> <p>The KHCCBIO bank intends to change this situation in the Middle East by establishing an ISO accredited biospecimen repository at the King Hussein Cancer Center (KHCC) for the storage and archival of biospecimens. KHCC is a specialized cancer center in the Middle East that treats both adult and pediatric cancer patients. Currently, over 3,500 new cancer patients arrive each year from Jordan and the neighboring countries Egypt, Iraq, Lebanon, Syria, Gulf Countries and North Africa.</p> 	<p>KHCCBIO Consortium for Bio-Banking Jordan- Ireland</p> <p>Funding program 7th Framework Program of the European Union (FP7)</p>  <p>Project start November 19, 2011</p> <p>Project duration 24 months</p> <p>Project budget 550,000 euro</p>	<p>This innovative approach is based on the application of a unique treatment protocol adapted for each patient separately and requires the need for reliable clinical data of the patient. This so-called personalized medicine should be able to reduce the negative effects and conclusively determine the receptiveness of the patient's response to the cancer treatment and prevention of cancer relapse.</p> <p>KHCCBIO bank will be developed for the purpose of collecting, processing, storing and distributing high-quality, clinically annotated surplus-cancer tissue specimens from consented patients. This novel, Jordan-based biobank will also standardize and define collection of biological samples for patient-oriented research, to include hypothesis-driven collections, as well as collections for questions arising, for the ultimate improvement of patient diagnosis, prognosis, treatment and leading to a more personalized approach to healthcare.</p> <p>KHCCBIO covers a range of support activities that are needed to establish, operate and maintain sustainably a cancer biobank. The biobank related activities will incorporate all current international guidelines and best-in-class practices under an approved Quality Management System to procure, process and store biospecimens for the benefit of researchers in Jordan, its neighboring countries, European researchers and researchers throughout the rest of the world.</p> <p>The KHCCBIO banking project has been conceived to create a world-class, ISO accredited biobank in the King Hussein Cancer Centre (KHCC), Amman, Jordan to be used for research into new treatments for diseases. KHCCBIO will have major impact and contribute to medical advances by providing high-quality human biospecimens and data to the cancer research communities world-wide. KHCCBIO will contribute to capacity building and management in Jordan and neighboring countries, increase scientific excellence and efficacy of Jordanian research in biomedical sciences, and better integrate Jordanian science and medicine with its European neighbors resulting in enhanced participation of Jordanian organization in the Seventh Framework Program.</p>	<p>Project coordinator Dr. Maher A. Sughayer</p> <p>Full Member and Chairman Department of Pathology and Laboratory Medicine King Hussein Cancer, Jo</p> <p>Chief Quality Officer & Deputy Coordinator Dr. Lina Souan Director, Clinical Immunology Lab. & Chair, Quality Management & Safety Committee Dept. of Pathology & Lab. Medicine King Hussein Cancer, Jo</p> <p>Project participants Accelopment AG, CH Biostor Ltd, Ireland Trinity College, Ireland</p>
--	--	---	---

Second Flyer


KING HUSSEIN CANCER FOUNDATION
KING HUSSEIN CANCER CENTER
KHCCBIO


KHCCBIO - Supporting the Establishment of a Cancer Biobank for Jordan and its Neighboring Countries Through Knowledge Transfer and Training

ISSUE 02 - June 2013

The scope of KHCCBIO is to collect, process, store and distribute high-quality, clinically annotated surplus-cancer tissue specimens from consented patients. This innovative approach is based on the application of personalized medicine which should reduce the deleterious side effects and determine the receptiveness of the patients' response to cancer treatment as well as prevent cancer relapse. It will also standardize and define collection of biological samples for patient-oriented research, to include hypothesis-driven collections, as well as collections for questions arising, for the ultimate improvement of patient diagnosis, prognosis, treatment and leading to a more personalized approach in healthcare.

Activities:

KHCCBIO Kick off Meeting
 KHCCBIO project was first launched by holding the kickoff meeting in Amman – Jordan, from 19th to 21st November – 2011 at King Hussein Cancer Center (KHCC). Representatives from all partners attended the meeting and they were: Dr. Maher Sughayen, Chairman of Pathology and Laboratory Medicine at KHCC, Dr. Lina Souan, head of the clinical Immunology Laboratory at KHCC and chief Quality officer for KHCCBIO. Dr. Martin Barr, Clinical Scientist & Adjunct Assistant Professor and Dr. Kathy Gately, Clinical Scientist & Lecturer at Trinity College Dublin from Trinity College Dublin. Mr. Peadar MacGabhann, the CEO of Biostör Ireland Limited and Mr. Uwe Kuhn financial manager of Biostör Ireland. Finally, Dr. Jeanette Müller the CEO of Accelopment AG (ACCEL).

The first consortium meeting
 The first consortium meeting was held at KHCC in Amman, Jordan from May 26th–May 29th, 2013. KHCCBIO collaborators who attended the meeting were Mr. Peadar MacGabhann the CEO of Biostör, Ireland and Dr. Martin Barr Clinical Scientist and Lecturer, Thoracic Oncology, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James's Hospital and TCD, Dublin, Ireland from Trinity College Dublin.



Funding program
 7th Framework Program of the European Union (FP7)

Project start
 November 19, 2011

Project duration
 30 months

Project budget
 550,000 euro

Website:
<http://Khccbio.khc.jo>

Address: Amman, Jordan queen Rania street

Telephone: +962-76-5300460
Fax: 5342567

P.O.Box: 1269
 Al-Jubriha Amman
 11941

On behalf of KHCCBIO, King Hussein Cancer Center; Dr. Maher Sughayen, Chairman of the department of Pathology & Laboratory Medicine and director of KHCCBIO bank, Dr. Lina Souan, Director of the Clinical Immunology Laboratory and Chief Quality Officer and Deputy Director of KHCCBIO Tissue Bank, Dr. Maxim Al Ashhab, pathologist, Khitam Hamza and Mohamed Jasser, medical technologists, and Salam Alhassoon, KHCCBIO document controller.

A four day-workshop was held during the annual meeting to discuss the progress in the joint project and develop plans to assure the growth and stability of the first biobank in the area.

The partners discussed deliverables, IPPs, equipment and upcoming activities of the project. Furthermore, hands-on Training for KHCCBIO tissue-bank staff was held in house to assure the quality and validation of the procedures supervised by TCD and Biostör.

Deliverables fulfilled:

- KHCCBIO Quality Policy Manual and Validation Plan.
- Consent policy, consent SOP and forms and data privacy policy.
- Installation Qualification Protocol for the Equipment/System.
- Dissemination and exploitation plan
- Public website was launched in 2012.
- Several press releases and radio and TV interviews were conducted to promote the project and to increase public awareness.
- Project related brochures and newsletters were written and distributed.

Training:
 Training of the medical technologists, document controller and pathologist was held at TCD and Biostör in Ireland.

Upcoming events:
 2nd annual/final consortium meeting will be held in 2014.

International Middle-East Biohanking conference (final project event) will be held in 2014 to announce the opening of the first ISO compliant cancer Bio repository in Jordan and the region.


KING HUSSEIN CANCER FOUNDATION
KING HUSSEIN CANCER CENTER
KHCCBIO


البرنامج يدعم من
الاتحاد الأوروبي (FP7)



مدة المشروع
 30 شهر

بدء المشروع
 19/11/ 2011

ميزانية المشروع
 550,000 كف يورو

Website:
<http://Khccbio.khc.jo>

Address: Amman, Jordan queen Rania street

Telephone: +962-76-5300460
Fax: 5342567

P.O.Box: 1269
 Al-Jubriha Amman
 11941

إنشاء أول بنك حيوي لحفظ العينات السرطانية (KHCCBIO) في الأردن و البلدان المجاورة حسب معايير الجودة العالمية (ISO)
 العدد 2 - نوفمبر 2013

هو أول بنك ينطلياً تطبيق جميع الأنسجة السرطانية الثالثة من جاهة تشخيص المرض. وفقاً لأحدث معايير الجودة العالمية الـ ISO - 15223-1، وذلك لتسهيل اجراءات الجودة الطبية. و يجري تأسيس هذا البنك حالياً بالتعاون مع الأطراف الآردنية من خلال KHCCBIO يجري تطوير البنك لتضمين المعايير الطبية بطرق عالمية المطابقة من المعايير التقييمية. ويسعدنا هنا أن نحيط بالذكر على تطبيق المعايير الأفضل التي ينبع عن أن يقلل من المخاطر السلبية لخالع المرضى و يزيد من استدامة المعايير الطبية للعلاج والوقاية من الآثار غير المرغوب بها. وهذا يسهم في توحيد وتعريف و تطبيق العينات المبوليوجية للابحاث التي تستند على تطبيق بروتوكول عالي القيمة في كل مرحلة على حداً اعتماداً على بيانات موثقة خاصة بحالات المرضى بعد الحصول على موافقاتهم الخطية. يجدر بنا في الاعتناء بالجودة على خصوصية كل مريض.

فعاليات بنك الأنسجة
 المؤتمر الأول لإعلان انطلاق المشروع

أطلق مشروع بنك KHCCBIO من خلال عقد مؤتمر في مركز المحسن للسرطان عمان -الأردن من 19-21 نوفمبر - 2011. يحضور جميع شركاء KHCCBIO التالية أسمائهم: الدكتور ماهر سعفان، قسم الأنسجة الرودينية و المختبرات، و المديرة لينا سوان، رئيسة قسم المعايير و مسؤولة الجودة في بنك الأنسجة المرضية في KHCCBIO في مركز المحسن للسرطان، والشركاء من الأطراف الآردنية السيد بيدر ماكجوان و أفراد كون من شركة بيومستور، أيرلندا و المشرف على بنك الأنسجة الدكتور مارتن بار و المشرف على بنك الأنسجة الدكتور جانيت جاريت، و من شركة أسيبلومنت المختبرة جانيت جاريت.

الافتتاح



KING HUSSEIN CANCER FOUNDATION
KING HUSSEIN CANCER CENTER
KHCCBIO


منسق المشروع
 د. ماهر سعفان
 مدير قسم المختبرات و
 رئيسة قسم المعايير
 مركز المحسن للسرطان
 الأردن

**رئيس المجموعة
 التوعية و تابع
 المنشآت**
 د. لينا سوان
 رئيسة مختبر علم
 المعايير و مسؤولة قسم
 إدارة الجودة و المعايير
 قسم المختبرات و المعايير
 المرضية
 مركز المحسن للسرطان
 الأردن

**المشاترين في
 المشروع**
 شركة بيومستور
 أيرلندا
 كلية طب و تكنولوجيا
 علوم و تكنولوجيا
 سانت جونز،
 أيرلندا
 شركة أسيبلومنت
 سويسرا

التجرب العمل
 تم تدريب فني ألماني و بريطاني علم الأمراض من بنك الأنسجة KHCCBIO في كلية تيربيثيل، بلجيا و بيومستور أيرلندا على أحد المبادرات المفتوحة و تغير المعايير و المعايير المرضية لتضمين المعايير الأفضل على بنك الأنسجة KHCCBIO على أفضل المعايير على حفظ و ارشفة المعلومات و الوثائق المتعلقة بالبنك.

الفعاليات القادمة
 - مسقديد الاجتماع السنوي النهائي في عام 2014
 - تدريب المؤشر العالمي لبيان الأنسجة في عام 2014 في عمان الأردن و ذلك بهدف الإعلان عن افتتاح بنك الأنسجة السرطانية الأول KHCCBIO في الأردن و المنطقة.



List of all beneficiaries with the corresponding contact names

1. KHCC

Corresponding contact name and contact information:

Maher A. Sughayer MD, FCAP
Full Member and Chairman,
Pathology & Laboratory Medicine Dept.
King Hussein Cancer Center
P.O.Box 1269
Amman 1194, Jordan
Tel: +962-6-5300460 ext1551
Fax: +962-6-5300460 ext 1552
Mobile: +962-77-7491216

2. TCD

Corresponding contact name and contact information:

Dr. Martin Barr
Clinical Scientist & Adjunct Assistant Professor
Thoracic Oncology
Institute of Molecular Medicine
Trinity Centre for Health Sciences
St James's Hospital & Trinity College Dublin
Dublin 8, Ireland
Tel Office: +353-1-8963620
Tel Lab: +353-1-8962134
E-mail: mbarr@stjames.ie, barrma@tcd.ie

3. Biostór

Corresponding contact name and contact information:

Peadar Mac Gabhann
Biostór Ireland
Kilrane Business Park
Rosslare Harbour
Co Wexford
Ireland
t : +353 916 1398
m : +353 87 2427099
e : peadar@biostor.eu
www.biostor.eu

4. ACCEL

Corresponding contact name and contact information:

Dr. Jeanette Müller | CEO
accelopment AG | Seefeldstrasse 198
CH-8008 Zürich | Switzerland
Phone : +41 44 455 66 01 | Mobile : +41 79 750 65 73
Skype: [jeanette_mueller](skype:jeanette_mueller)
www.accelopment.com